Search

Your search keyword '"Agostoni E. C."' showing total 3 results
Start Over Author "Agostoni E. C." Language english
3 results on '"Agostoni E. C."'

1. Current and emerging evidence-based treatment options in chronic migraine: A narrative review

Author

Agostoni E. C., Barbanti P., Calabresi P., Colombo B., Cortelli P., Frediani F., Geppetti P., Grazzi L., Leone M., Martelletti P., Pini L. A., Prudenzano M. P., Sarchielli P., Tedeschi G., Russo A., The Italian chronic migraine group, Agostoni, E. C., Barbanti, P., Calabresi, P., Colombo, B., Cortelli, P., Frediani, F., Geppetti, P., Grazzi, L., Leone, M., Martelletti, P., Pini, L. A., Prudenzano, M. P., Sarchielli, P., Tedeschi, G., Russo, A., Agostoni E.C., Barbanti P., Calabresi P., Colombo B., Cortelli P., Frediani F., Geppetti P., Grazzi L., Leone M., Martelletti P., Pini L.A., Prudenzano M.P., Sarchielli P., Tedeschi G., Russo A., and The Italian chronic migraine group

Subjects
Botulinum Toxins, lcsh:Medicine, Review Article, Anti-CGRP monoclonal antibodies, Type A, 0302 clinical medicine, Chronic Migraine, Migraine Disorder, Monoclonal, Chronic migraine, Fremanezumab, onabotulinumtoxinA, Prophylaxis, Topiramate, Antibodies, Monoclonal, Botulinum Toxins, Type A, Chronic Disease, Disabled Persons, Humans, Migraine Disorders, Randomized Controlled Trials as Topic, 030212 general & internal medicine, Prophylaxi, anti-CGRP monoclonal antibodies, chronic migraine, fremanezumab, prophylaxis, topiramate, antibodies, monoclonal, botulinum toxins, type A, chronic disease, disabled persons, humans, migraine disorders, randomized controlled Trials as Topic, General Medicine, Settore MED/26 - NEUROLOGIA, Tolerability, Disabled Person, medicine.drug, Human, medicine.medical_specialty, Evidence-based practice, Pain medicine, Anti-CGRP monoclonal antibodie, Calcitonin gene-related peptide, Antibodies, 03 medical and health sciences, medicine, Intensive care medicine, business.industry, lcsh:R, medicine.disease, Clinical trial, Anesthesiology and Pain Medicine, Migraine, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract

Background Chronic migraine is a disabling condition that is currently underdiagnosed and undertreated. In this narrative review, we discuss the future of chronic migraine management in relation to recent progress in evidence-based pharmacological treatment. Findings Patients with chronic migraine require prophylactic therapy to reduce the frequency of migraine attacks, but the only currently available evidence-based prophylactic treatment options for chronic migraine are topiramate and onabotulinumtoxinA. Improved prophylactic therapy is needed to reduce the high burden of chronic migraine in Italy. Monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway of migraine pathogenesis have been specifically developed for the prophylactic treatment of chronic migraine. These anti-CGRP/R monoclonal antibodies have demonstrated good efficacy and excellent tolerability in phase II and III clinical trials, and offer new hope to patients who are currently not taking any prophylactic therapy or not benefitting from their current treatment. Conclusions Treatment of chronic migraine is a dynamic and rapidly advancing area of research. New developments in this field have the potential to improve the diagnosis and provide more individualised treatments for this condition. Establishing a culture of prevention is essential for reducing the personal, social and economic burden of chronic migraine.

Published
2019

2. Insomnia and menopause: a narrative review on mechanisms and treatments.

Author

Proserpio, P., Marra, S., Campana, C., Agostoni, E. C., Palagini, L., Nobili, L., and Nappi, R. E.

Subjects
HOT flashes, PREMATURE menopause, INSOMNIA, COGNITIVE therapy, SLEEP disorders, SYMPTOMS, AFFECTIVE disorders
Abstract

Copyright of Climacteric is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2020
Full Text
View/download PDF

3. Polysomnographic features differentiating disorder of arousals from sleep-related hypermotor epilepsy

Author

Paolo Tinuper, Paola Proserpio, Frédéric Zubler, Giuseppe Loddo, Federica Provini, Laura Tassi, Lino Nobili, Veronica Menghi, Luigi Ferini-Strambi, Elio Agostoni, Francesca Bisulli, Claudio L. Bassetti, Laura Licchetta, Proserpio, Paola, Loddo, Giuseppe, Zubler, Frederic, Ferini-Strambi, Luigi, Licchetta, Laura, Bisulli, Francesca, Tinuper, Paolo, Agostoni, Elio Clemente, Bassetti, Claudio, Tassi, Laura, Menghi, Veronica, Provini, Federica, Nobili, Lino, Proserpio, P., Loddo, G., Zubler, F., Ferini-Strambi, L., Licchetta, L., Bisulli, F., Tinuper, P., Agostoni, E. C., Bassetti, C., Tassi, L., Menghi, V., Provini, F., and Nobili, L.

Subjects
Adult, Male, Sleep Wake Disorders, medicine.medical_specialty, Adolescent, Polysomnography, Video Recording, Sleep-related hypermotor epilepsy, Disorder of arousal, Parasomnia, Arousal, Diagnosis, Differential, 03 medical and health sciences, Epilepsy, Young Adult, 0302 clinical medicine, Physiology (medical), Internal medicine, Medicine, Humans, Motor Manifestations, 610 Medicine & health, Event (probability theory), Aged, Retrospective Studies, medicine.diagnostic_test, business.industry, parasomnia, sleep-related hypermotor epilepsy, Electroencephalography, Middle Aged, medicine.disease, disorder of arousal, 030228 respiratory system, Cardiology, Female, Neurology (clinical), Sleep (system call), Differential diagnosis, business, Sleep, 030217 neurology & neurosurgery
Abstract

ObjectiveThe differential diagnosis between sleep-related hypermotor epilepsy (SHE) and disorders of arousal (DOA) may be challenging. We analyzed the stage and the relative time of occurrence of parasomnic and epileptic events to test their potential diagnostic accuracy as criteria to discriminate SHE from DOA.MethodsVideo-polysomnography recordings of 89 patients with a definite diagnosis of DOA (59) or SHE (30) were reviewed to define major or minor events and to analyze their stage and relative time of occurrence. The “event distribution index” was defined on the basis of the occurrence of events during the first versus the second part of sleep period time. A group analysis was performed between DOA and SHE patients to identify candidate predictors and to quantify their discriminative performance.ResultsThe total number of motor events (i.e. major and minor) was significantly lower in DOA (3.2 ± 2.4) than in SHE patients (6.9 ± 8.3; p = 0.03). Episodes occurred mostly during N3 and N2 in DOA and SHE patients, respectively. The occurrence of at least one major event outside N3 was highly suggestive for SHE (p = 2*e-13; accuracy = 0.898, sensitivity = 0.793, specificity = 0.949). The occurrence of at least one minor event during N3 was highly suggestive for DOA (p = 4*e-5; accuracy = 0.73, sensitivity = 0.733, specificity = 0.723). The “event distribution index” was statistically higher in DOA for total (p = 0.012) and major events (p = 0.0026).ConclusionThe stage and the relative time of occurrence of minor and major motor manifestations represent useful criteria to discriminate DOA from SHE episodes.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results